Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2004

View Archived Issues

Long-acting dipeptidyl-peptidase IV inhibitor ameliorates insulin resistance

New data on the use of SC-1 in the treatment of gastric cancer

Tocosol paclitaxel found safe and effective against advanced tumors in humans

Phase II trials of Levulan PDT in high-grade dysplasia in Barrett's esophagus and facial photodamage

Bradley Pharmaceuticals to acquire Bioglan

Enrollment opens in pivotal trial of doripenem for hospital-acquired pneumonia

Enrollment completed in Angiotech vascular wrap study

Completion of phase IIa study of AeroLEF in postsurgical patients

CytRx completes licensing deal with SynthRx

Oblimersen sodium reported to increase the antitumor efficacy of dacarbazine in malignant melanoma

Results of phase III trials of rimonabant in metabolic syndrome and smoking presented

Combined drug therapy reduces cocaine use with limited abuse potential in primates

Novel dual PPAR agonist with hypoglycemic and hypolipidemic effects

MMP inhibitor BAY-15-7496 shows potential for the treatment of COPD

Disappointing results from emfilermin proof-of-concept study

Phase I/II study for Merix's renal cancer vaccine

Altocor product name changed to Altoprev

PRECISE study to evaluate PhosLo plus Lipitor combination therapy

Astex Technology extends structural biology research agreement with Aventis

Ganymed licenses WT1 immunotherapy rights to Corixa and Kirin Brewery

Leo Pharma shuts HL-10 phase III study

LigoCyte executes norovirus vaccine agreement with Baylor College of Medicine

Incyte offers drug discovery and development update

Corixa highlights first quarter accomplishments

Non-calcemic vitamin D analogues for use in secondary hyperparathyroidism

New Rho kinase inhibitors in early development at Bayer

Two series of beta2-adrenoceptor agonists patented by GSK researchers

Two series of MCH antagonists identified at Boehringer Ingelheim

Bayer scientists present novel CETP inhibitors

Inhibitors of prostaglandin and leukotriene production developed at Wakamoto

Boehringer Ingelheim scientists describe new beta3-adrenoceptor agonists